These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 19667545)

  • 1. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic antimicrobial agents for postoperative infections: appropriate use of antibiotics from the viewpoint of pharmacokinetic/pharmacodynamic theory].
    Takesue Y; Nakajima K; Wada Y; Ichiki K; Yanagi H; Ikeuchi H
    Nihon Geka Gakkai Zasshi; 2006 Sep; 107(5):224-9. PubMed ID: 17017418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood and respiratory diffusion of antibiotics. A critical analysis of predictive parameters for clinical effectiveness].
    Fantin B
    Med Mal Infect; 2006; 36(11-12):599-613. PubMed ID: 16837154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing an antibiotic on the basis of pharmacodynamics.
    Craig WA
    Ear Nose Throat J; 1998 Jun; 77(6 Suppl):7-11; discussion 11-2. PubMed ID: 9674328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection.
    Frimodt-Møller N
    Dan Med Bull; 1988 Oct; 35(5):422-37. PubMed ID: 3066588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical implications of antibiotic pharmacokinetic-pharmacodynamic parameters].
    Cohen R
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S53-8. PubMed ID: 19000855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.
    Drusano GL; Craig WA
    J Chemother; 1997 May; 9 Suppl 3():38-44. PubMed ID: 9248979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy.
    Auckenthaler R
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():13-7. PubMed ID: 12077155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the dose matter?
    Craig WA
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S233-7. PubMed ID: 11524724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.